SAN DIEGO, Oct. 6, 2017 /PRNewswire/ –Â Janssen Pharmaceutica, NV announced formula from a pivotal Phase 3 EMERALD investigate that were published now online in The Lancet HIV and will be presented during IDWeek 2017 in San Diego. The investigate met a primary endpoint, that focused on virologic miscarry rate, and demonstrated that switching to a investigational single-tablet fast (STR) containing darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg (D/C/F/TAF) was non-inferior to stability diagnosis with a increased protease inhibitor (PI) and emtricitabine and tenofovir disoproxil fumarate in tellurian immunodeficiency pathogen form 1 (HIV-1) positive, virologically suppressed adults. There were no celebrated insurgency compared mutations (RAMs) to investigate drugs by 48 weeks. If authorized in a U.S., D/C/F/TAF would be a usually finish fast that might broach a intensity confluence advantage of a once-daily STR with a continuance and high genetic separator to insurgency of darunavir and a demonstrated bone and renal reserve form of TAF.
“When people who are diagnosed with HIV don’t belong to their diagnosis regimen, they can build adult drug resistance, that can describe their diagnosis â€“ and even an whole category of treatments â€“ ineffective,” pronounced Joseph Eron, MD, Professor of Medicine and Director, Clinical Core, University of North Carolina Center for AIDS Research, Chapel Hill, NC. “The commentary from a EMERALD investigate move us one step closer to being means to offer those who live with HIV and onslaught with confluence an choice that combines a efficiency and high genetic separator to insurgency of darunavir with a demonstrated reserve form of tenofovir alafenamide into a singular tablet.”
About a EMERALD clinical hearing
The Phase 3 EMERALD investigate is a randomized (2:1), open-label, international, multi-center, parallel-group, non-inferiority, 48-week investigate evaluating a efficiency and reserve of switching to D/C/F/TAF contra stability with a increased PI (lopinavir/ritonavir, atazanavir or darunavir increased by possibly ritonavir or cobicistat) and emtricitabine/tenofovir disoproxil fumarate in adult HIV-1 putrescent patients who are virologically suppressed (viral bucket [VL]
Through 48 weeks, accumulative virologic miscarry was 2.5% (D/C/F/TAF, n=19) vs. 2.1% (control, n=8) with 12/19 in D/C/F/TAF and 4/8 in a control organisation re-suppressed (
D/C/F/TAF also demonstrated identical reserve contra control organisation by 48 weeks.Â Rates of discontinuations due to inauspicious events (AEs) were 1.4% (D/C/F/TAF) vs. 1.3% (control); Grade 3-4 AEs were 6.8% (D/C/F/TAF) vs. 8.2% (control); and critical AEs were 4.6% (D/C/F/TAF) vs. 4.8% (control). There were no deaths in possibly arm of a study. The many common AEs were nasopharyngitis (D/C/F/TAF 10.6% vs. control 10.3%), top respiratory tract infection (10.6% vs. 10.3%), and diarrhea (7.9% vs. 4.2%).
“At Janssen, we are committed to building a extended operation of therapies to accommodate a different needs of a HIV community,” pronounced Magda Opsomer, MD, Senior Director, Clinical Leader, Janssen Infectious Diseases. “Today, stigma, lifestyle and tablet weight continue to emanate confluence hurdles for many people vital with HIV. If approved, a darunavir STR would be an critical choice that might assistance residence these confluence barriers by charity a once daily, single-pill dosing fast with a high genetic separator to insurgency of darunavir.”
On September 25, 2017, a European Commission authorized a use of D/C/F/TAF for a diagnosis of HIV-1 infection in adults and teenagers aged 12 years and comparison with physique weight of during slightest 40 kg. This capitulation allows Janssen to marketplace D/C/F/TAF in all member states of a European Union and a European Economic Area. In a U.S., D/C/F/TAF is an investigational product. A new drug focus (NDA) was filed on September 22, 2017 to a U.S. Food and Drug Administration (FDA), and is now accessible approval. The NDA was filed for a diagnosis of HIV-1 infection in adults and pediatric patients 12 years of age and comparison and was formed on a formula from dual pivotal Phase 3 studies, EMERALD and AMBER. AMBER is a 48-week, double-blind, non-inferiority investigate evaluating a efficiency and reserve of D/C/F/TAF in antiretroviral therapy (ART) treatment-naÃ¯ve patients. Phase 3 AMBER information by 48 weeks will be presented during a arriving European AIDS Conference, October 25-27, 2017 in Milan, Italy.
To learn some-more about Janssen’s joining to a impediment and diagnosis of HIV, greatfully revisit jnj.com/HIV.
Notes to editors
Cobicistat, emtricitabine and tenofovir alafenamide are from Gilead Sciences, Inc. On December 23, 2014, Janssen and Gilead Sciences Inc. nice a chartering agreement for a growth and commercialization of a once-daily STR multiple of darunavir and Gilead’s TAF, emtricitabine and cobicistat. Under a terms of a agreement, Janssen and a affiliates are obliged for a manufacturing, registration, placement and commercialization of this STR worldwide.
For some-more information on a clinical trials greatfully visit: www.clinicaltrials.gov
At Janssen, we are operative to emanate a universe though disease.Â Transforming lives by anticipating new and improved ways to prevent, intercept, provide and heal illness inspires us. We move together a best minds and pursue a many earnest science. We are Janssen. We combine with a universe for a health of everybody in it. Learn some-more during www.janssen.com. Follow us during www.twitter.com/JanssenUS and www.twitter.com/JanssenGlobal.
Cautions Concerning Forward-Looking Statements
This press recover contains “forward-looking statements” as tangible in a Private Securities Litigation Reform Act of 1995 per a advantages and intensity capitulation of a new diagnosis choice for HIV-1. The reader is cautioned not to rest on these forward-looking statements. These statements are formed on stream expectations of destiny events. If underlying assumptions infer false or famous or different risks or uncertainties materialize, tangible formula could change materially from a expectations and projections of Janssen Pharmaceutica NV, any of a other Janssen Pharmaceutical Companies and/or Johnson Johnson. Risks and uncertainties include, though are not singular to: hurdles and uncertainties fundamental in product development, including doubt of clinical success and receiving regulatory approvals; doubt of blurb success; production problems and delays; competition, including technological advances, new products and patents achieved by competitors; hurdles to patents; changes to germane laws and regulations, including tellurian health caring reforms; and trends toward health caring cost containment. A serve list and outline of these risks, uncertainties and other factors can be found in Johnson Johnson’s Annual Report on Form 10-K for a mercantile year finished January 1, 2017, including underneath “Item 1A. Risk Factors,” a many recently filed Quarterly Report on Form 10-Q, including underneath a heading “Cautionary Note Regarding Forward-Looking Statements,” and a company’s successive filings with a Securities and Exchange Commission. Copies of these filings are accessible online during www.sec.gov, www.jnj.com or on ask from Johnson Johnson. None of a Janssen Pharmaceutical Companies or Johnson Johnson undertakes to refurbish any forward-looking matter as a outcome of new information or destiny events or developments.
rel=”nofollow”Rgenin1@its.jnj.comÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â
INVESTOR RELATIONS:Â Â Â
Joseph J. Wolk
View strange content:http://www.prnewswire.com/news-releases/janssen-announces-pivotal-phase-3-study-results-for-investigational-darunavir-based-single-tablet-regimen-for-the-treatment-of-hiv-1-infection-in-adults-switching-from-boosted-protease-inhibitors-plus-emtricitabine-and-tenofovir-d-300532663.html
SOURCE Janssen Pharmaceutica, NV